To investigate the underlying immune mechanisms responsible for different infection rate during treatment with anti-BCMA vs GPRC5D bsAb
Latest Information Update: 18 Feb 2025
At a glance
- Drugs Elranatamab (Primary) ; Talquetamab (Primary) ; Teclistamab (Primary) ; Immunomodulators; Monoclonal antibodies
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 18 Feb 2025 New trial record